长链非编码RNA DLX6-AS1在肿瘤中的研究进展  

Research progress on long non-coding RNA DLX6-AS1 in tumors

作　　者：段秋香 陈程[1] 彭彬峰 姜孝新[1] Duan Qiuxiang;Chen Cheng;Peng Binfeng;Jiang Xiaoxin(Department of Laboratory Medicine,the First Affiliated Hospital of Nanhua University,Hengyang 421000,China)

机构地区：[1]南华大学附属第一医院检验科,衡阳421000

出　　处：《新医学》2020年第12期896-901,共6页Journal of New Medicine

基　　金：湖南省自然科学基金(2019JJ80035)。

摘　　要：近年来,长链非编码RNA(lncRNA)可作为抑癌或促癌因子参与肿瘤的多种生物过程,包括增殖、抗凋亡、侵袭和迁移,其异常表达与患者预后、临床病理学特征及耐药紧密相关。DLX6-AS1是最近发现的一种新型lncRNA,其在多种恶性肿瘤中表达上调,并与肿瘤预后、TNM分期、淋巴结转移和远处转移相关,且可与多种微小RNA相互作用调节下游靶基因及相关信号通路发挥促癌作用。该文就lncRNA DLX6-AS1参与人类肿瘤的生物学过程和调控机制作一综述。In recent years,long non-coding RNA(lncRNA)has been reported to be involved in a variety of tumor biological processes as a tumor suppressor or tumor-promoting factor,including proliferation,anti-apoptosis,invasion and migration.Abnormal expression of lncRNA is closely correlated with patient prognosis,clinicopathological characteristics and drug resistance.As a newly-discovered lncRNA,DLX6-AS1 is abnormally expressed in a variety of malignant tumors,which is positively correlated with poor tumor prognosis,late stage,lymph node metastasis and distant metastasis.DLX6-AS1 interacts with microRNA to regulate the downstream target genes and signaling pathways and promote tumorigenesis.In this article,the role and regulatory mechanism of DLX6-AS1 in the biological process of human tumors were reviewed.

关 键 词：长链非编码核糖核酸 DXL6-AS1 微小核糖核酸 肿瘤 

分 类 号：R730.2[医药卫生—肿瘤]